WCN26-2804 EFFECTS OF SGLT- 2 INHIBITORS ON ENDOTHELIAL FUNCTION IN CKD: ROLE OF THE eNOS T(-786)C POLYMORPHISM

Read full text Summarise with VIRAT
Authors: SHALALA G ISMAYILOVA, Ayten Mammmadzada, Azada Alekberova, A. S. Rahimova, Farida Hajıyeva, Shefeg Ibrahimova, N. S. Huseynova
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Endothelial dysfunction is a major contributor to cardiovascular morbidity in patients with chronic kidney disease (CKD). Sodium-glucose co-transporter-2 (SGLT-2) inhibitors, such as dapagliflozin and empagliflozin, provide cardiovascular and renal protection beyond their glucose-lowering effects, partly by improving endothelial function. Variations in the endothelial nitric oxide synthase (eNOS) gene, particularly the T(-786)C polymorphism, may alter nitric oxide (NO) bioavailability and influence vascular responses to these agents.

Fields of Study & Subjects

Nitric Oxide and Endothelin Effects Diabetes Treatment and Management Chronic Kidney Disease and Diabetes

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105723–105723
Publication date
25 March 2026
Language
EN